Posts for the 'MRI Contrast' Category
Schedule for Scientific Symposium on Nephrogenic Systemic Fibrosis
Nephrogenic systemic fibrosis, which has also been referred to as nephrogenic fibrosing dermopathy, is a rare condition which has been associated with the use of gadolinium based MRI contrast agents among individuals with moderate to severe kidney failure. Next month, Yale University will be hosting the Second Annual Symposium on Nephrogenic System Fibrosis and Gadolinium Containing Agents to address the latest developments surrounding this relatively new condition, including mechanisms of the disease, clinical approaches and risk reduction. In advance of the May 10, 2008 conference, the schedule of what will be presented has been released.
Second annual conference on NSF/NFD and MRI contrast agents
On May 10, 2008 in New Haven, CT, Yale University will host the Second Annual Scientific Synposium on Nephrogenic Systemic Fibrosis (NSF/NFD) and MR Gadolinium-based contrast agents. The conference will present the latest developments regarding the serious and debilitating condition which has been associated with the use of MRI contrast agents when given to individuals with impaired kidney function.
>>INFORMATION: NSF/NFD and MRI Contrast Agents
Study confirms link between NSF and MRI dye: Lawsuits are being reviewed nationwide
A study published in the October 2007 issue of Radiology, confirms the link between gadolinium based MRI dye used as a contrast agent during magnetic resonance imaging (MRI) and the development of nephrogenic systemic fibrosis (NSF) for individuals with kidney failure. The lawyers at Saiontz, Kirk & Miles, P.A. represent individuals nationwide who have been diagnosed with NSF who are pursing an MRI dye lawsuit to obtain compensation for the painful and debilitating condition which could have been prevented if proper warnings had been issued.
>>INFORMATION: MRI Dye Lawsuits
Risk of NSF and death rate higher than previously thought
A new study on nephrogenic systemic fibrosis (NSF) confirms a definite and strong association between the use of gadolinium based contrast agents during an MRI and the development of the debilitating condition for those with kidney problems. Researchers also found that the NSF death rate and risk of developing the condition may be much higher than originally thought for dialysis patients.
>>INFORMATION: Gadolinium contrast linked to NSF
Research may provide keys to preventing and treating NSF
The use of gadolinium based MRI contrast agents has been directly linked to the development of nephrogenic systemic fibrosis (NSF) among individuals with kidney problems. Although it is known that the MRI contrast causes the painful and debilitating condition, researchers have been unsure of exactly why. A new study provides a possible explanation, and could lead to a strategy for preventing and treating NSF.
>>INFORMATION: MRI Contrast Side Effects Linked to NSF
MRI contrast kidney problem warnings added for risk of NSF
Yesterday the makers of MRI contrast agents containing gadolinium announced the language of a “black box” warning they have added to the labels of their products. They also released a letter which was sent to healthcare providers notifying them of the risk of nephrogenic systemic fibrosis among those with kidney problems. This finalizes the warnings which the FDA requested in May 2007.
>>INFORMATION: MRI Contrast Kidney Problems
MRI problems should have been disclosed sooner
Gadolinium based MRI contrast agents have been linked to the development of nephrogenic systemic fibrosis (NSF) in individuals with kidney insufficiencies. If the manufacturers of these contrast agents had properly conducted studies of their product or analyzed reports and other clinical data, they could have warned earlier about the potential MRI problems. Earlier warnings may have prevented the disabling and painful condition experienced by hundreds, or potentially thousands, of individuals.
>>INFORMATION: MRI Contrast Problems
Treatment for NSF and other rare conditions may not be covered by insurance
Many individuals diagnosed with nephrogenic systemic fibrosis (NSF), and other rare conditions which only impact a few hundred or a few thousand people, may experience difficulty obtaining insurance coverage for treatments which could improve their condition. Insurers often refuse to pay for treatments they consider “experimental” since there have not been enough individuals diagnosed with the condition to fully study the effectiveness of the therapy.
Link between Nephrogenic Systemic Fibrosis and Gadolinium
An article in the current issue of the New England Journal of Medicine offers an explanation why gadolinium based MRI contrast agents may cause Nephrogenic Systemic Fibrosis (NSF) in those with kidney insufficiencies. NSF has been directly linked to the use of gadolinium, and it has devastating consequences for those who develop the condition.
>>INFORMATION: Gadolinium and Nephrogenic Systemic Fibrosis
FDA Video: MRI contrast dye warnings due to risk of NSF
The latest edition of the FDA Patient Safety News webcast features a segment about the dangers of MRI contrast agents containing gadolinium. For individuals with kidney failure, the MRI contrast dyes could lead to a serious condition called nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing demopathy (NFD).
>>INFORMATION: MRI Contrast Dye Problems
